STAT+: Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs
WASHINGTON — Sen. Ron Wyden (D-Ore.), the influential chair of the Senate Finance Committee, is promising that his signature drug pricing package won’t eviscerate small biotech companies.
Wyden, typically a fierce critic of the drug industry, is suddenly giving a shoutout to small biotech companies and their role in developing “groundbreaking new treatments.” He’s even promising that the package he is crafting “can be tailored to the scale of these companies, as well as other factors that affect their access to capital.”
